Frequent Mutation of the *PIK3CA* Gene in Ovarian and Breast Cancers

Douglas A. Levine,¹ Faina Bogomolniy,¹ Cindy J. Yee,¹,² Alex Lash,³ Richard R. Barakat,¹ Patrick I. Borgen,¹ and Jeff Boyd¹,²

Abstract  Purpose: Activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, resulting in increased cell proliferation, survival, and motility, is believed to play an oncogenic role in many cancer types. The *PIK3CA* gene encodes the p110α catalytic subunit of PI3K, and is amplified in some ovarian cancers, whereas the *AKT2* gene is amplified in some ovarian, breast, and pancreatic cancers. Recently, in a mutational screen of eight PI3K genes and eight PI3K-like genes, *PIK3CA* was found to be the only gene affected by somatic mutations, which were observed frequently in gastrointestinal and brain cancers. Here, we test whether *PIK3CA* is subject to mutation in ovarian and breast cancers.

Experimental Design: Exons 9 and 20, encoding the highly conserved helical and kinase domains of *PIK3CA*, were subjected to sequence analysis in 198 advanced stage epithelial ovarian carcinomas and 72 invasive breast carcinomas (48 of ductal histology and 24 of lobular histology).

Results: Somatic missense mutations were observed in 24 of 198 (12%) ovarian carcinomas, and in 13 of 72 (18%) breast carcinomas.

Conclusions: These data indicate that mutations of *PIK3CA* play an oncogenic role in substantial fractions of ovarian and breast carcinomas, and in consideration of mutation of other components of the PI3K-AKT pathway in both tumor types, confirm the major oncogenic role of this pathway in ovarian and breast carcinomas.

Increased mitogenic signaling through receptor tyrosine kinases has been proven to play a major role in human tumorigenesis. One of the major downstream mediators of signaling initiated by these receptors is the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Several components of this signaling system are dysregulated in a wide variety of cancer types, including amplification and/or overactivation of *AKT2* and *PIK3CA* (encoding the p110 catalytic subunit of PI3K), mutation of *PIK3R1* (encoding the p85 regulatory subunit of PI3K), and mutational inactivation or silencing of the *PTEN* gene, a tumor suppressor that negatively regulates this pathway (1). Such deregulation of this pathway promotes a number of phenotypic properties associated with tumorigenesis, including increased cell proliferation, glucose transport and catabolism, cytoskeletal rearrangements, cell adhesion and migration, and decreased apoptosis. With respect to ovarian cancer, aberrations in components of this pathway include elevated AKT1 kinase activity (2), AKT2 amplification (3), *PIK3CA* amplification (4), *PIK3R1* mutation (5), and allelic imbalance and mutation of the *PTEN* gene (6). In breast cancers, AKT2 amplification (3) and elevated kinase activities of AKT1 (2) and PI3K (7) are observed.

Recently, a large-scale sequence analysis of 16 PI3K or PI3K-like genes revealed tumor-specific somatic mutations in only one of these genes, *PIK3CA* (8). All were apparent activating missense mutations, occurring primarily in the p85, C2, helical, or kinase functional domains. The great majority of mutations (85%) were present in exons 9 and 20, partially encoding the helical and kinase domains, respectively. Of the seven tumor sites studied, mutations were most common in colon (32%), glioblastoma (27%), and gastric (25%) cancers. Mutations were observed in 1 of 12 (8%) breast cancers; ovarian cancers were not examined. The purpose of this study was to use relatively large sample sizes to test whether activating mutations of the *PIK3CA* gene play a significant role in ovarian and breast tumorigenesis.

**Materials and Methods**

This study was approved by the Institutional Review Board of the Memorial Sloan-Kettering Cancer Center. Flash-frozen primary tumor specimens and corresponding normal tissues or blood samples were retrieved from a tissue bank maintained by the Gynecology and Breast Research Laboratory of the Department of Surgery at this institution. Following pathologic review to confirm diagnosis, tumor tissue was microdissected and genomic DNA was isolated from these tissues using seq...
standard techniques. A total of 198 unselected, advanced surgical stage (III or IV), moderately or poorly differentiated (Federation Internationale des Gynaecologistes et Obstetristes grades 2 or 3) invasive epithelial ovarian carcinomas were analyzed. A total of 72 unselected, invasive breast carcinomas were analyzed, 48 of ductal histology and 24 of lobular histology. The majority (78%) of the breast carcinomas were of early stage. Using PCR primers previously specified (8), exons 9 and 20 of PIK3CA were sequenced directly using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI 3730 automated capillary sequencer. Analyses of all PCR products with sequence variants were repeated for confirmation. Genomic DNA from corresponding normal tissue or blood samples was isolated and subjected to sequence analysis to confirm the somatic nature of tumor mutations. A representative example of sequencing data is shown in Fig. 1. The VMD molecular visualization program (http://www.ks.uiuc.edu/Research/vmd/) was used to prepare Fig. 2.

Results and Discussion

Somatic missense mutations in the PIK3CA gene were identified in 24 of 198 (12%) ovarian carcinomas and 13 of 72 (18%) breast carcinomas (Table 1). Since mutation analysis was limited to the exons encoding the helical and kinase domains of PIK3CA, where 85% of previous mutations were reported (8), these figures may represent underestimates of the true mutation frequencies in these tumor types. For ovarian cancers, 22 of 24 (92%) mutations occurred at codon 545 within the helical domain, a codon affected by 26% of all previously reported mutations (when the entire gene is analyzed). The other two ovarian cancers with mutations were affected at codon 1043 in the kinase domain, a mutation not previously reported, and at codon 1047, the second most common mutation previously reported. In addition, four synonymous mutations, three at codon 1025 and one at codon 1049, were also observed in ovarian cancers. For breast cancers, the mutations were somewhat less clustered than for ovarian cancers; 5 of 13 (38%) mutations occurred at codon 545, whereas 4 of 13 (31%) occurred at codon 542, and a similar number occurred at codon 1047. Mutations at all of these PIK3CA codons are frequently seen in other tumor types (8). Three breast tumors also contained the same synonymous mutation at codon 1025. The functional significance of the H1047R mutation has been described (8). Furthermore, it was recently reported that somatic mutations of PIK3CA in ovarian cancers occur almost to the exclusivity of gene amplification (9).

To gain further insight into the potential structural and functional implications of the mutations identified in this study, we attempted to model the PIK3CA protein. The crystal structure of PIK3CA has not yet been described, but the structure of the highly homologous PIK3CG protein is known (Protein Data Bank, 1E8Z). In the helical domain, the E542K mutation changes the charge from negative to strongly positive. At codon 545, where most of the ovarian carcinoma mutations occurred, the mutation resulted in a charge change from negative to highly positive (E545K), or caused it to become hydrophobic (E545G and E545A). As shown in Fig. 2, both of these residues are on the exposed surface of the molecule. These changes in charge may

Table 1. Summary of PIK3CA mutations in ovarian and breast cancers

<table>
<thead>
<tr>
<th>Exon</th>
<th>Nucleotide</th>
<th>Codon</th>
<th>Domain</th>
<th>Ovarian*</th>
<th>Breast†</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>G1624A</td>
<td>E542K</td>
<td>Helical</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>9</td>
<td>G1633A</td>
<td>E545K</td>
<td>Helical</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>9</td>
<td>A1634G</td>
<td>E545G</td>
<td>Helical</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>A1634C</td>
<td>E545A</td>
<td>Helical</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>C3075T</td>
<td>T1025T</td>
<td>Kinase</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>20</td>
<td>A3127G</td>
<td>M1043V</td>
<td>Kinase</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>A3140T</td>
<td>H1047L</td>
<td>Kinase</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>20</td>
<td>A3140G</td>
<td>H1047R</td>
<td>Kinase</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>20</td>
<td>T3147G</td>
<td>G1049G</td>
<td>Kinase</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total tumors with missense mutations</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Number of tumors screened</td>
<td>198</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Percentage of tumors with missense mutations</td>
<td>12%</td>
</tr>
</tbody>
</table>

*Number of ovarian cancers with the specified mutation.
†Number of breast cancers with the specified mutation.
‡Synonymous mutation.
therefore affect protein-protein or other intermolecular interactions. This region of the PIK3CG surface is believed to interact with other proteins, and it is reasonable to assume that similar interactions occur in the highly homologous PIK3CA (10). This helical domain of PIK3CG consists of five A/B pairs of antiparallel helices. Mutations in similar motifs of the PP2A PR65/A subunit have been shown to prevent intramolecular binding with PP2Ac and disrupt protein conformation (11).

The mutations in the kinase domain at codon 1047 change the amino acid charge from positive to hydrophobic (H1047L) or to strongly positive (H1047R). These two mutations and the M1043V mutation are located within the kα11 helix (Fig. 2). This helix is found between kα10 and kα12, which lie on two sides of the activation loop. Mutations in the activation loop have been shown to affect the specificity of lipid substrates and access to the catalytic core of PIK3CA (12). Mutations in the kα11 helix shown in this study may affect the function of the kinase domain, although biochemical data to support this hypothesis are lacking.

There were no correlations observed between the presence of PIK3CA mutation and any clinicopathologic feature of the ovarian cancers, such as stage, grade, histologic type, patient age, or survival. These data add to a growing body of literature implicating the PI3K-AKT pathway as playing a major oncogenic role in ovarian tumorigenesis, with a substantial proportion of these tumors having sustained amplification or mutation of PIK3CA, mutation of PIK3R1, amplification of AKT2, or mutational inactivation of PTEN. Notably, PIK3CA represents one of very few established human oncogenes that is commonly activated through either amplification or point mutation. Clinically, the clustering of mutations at codon 545 provides a convenient opportunity for early detection or monitoring for recurrence in the fraction of ovarian cancers with this mutation, and the common activation of the PI3K-AKT pathway in ovarian cancers generally suggests a possible therapeutic opportunity for pharmacologic intervention.

In breast cancers, the presence of a PIK3CA mutation did not correlate with clinicopathologic findings such as age at diagnosis, hormone receptor status, or histologic subtype (data not shown). Activating mutation of PIK3CA represents one of the most common oncogenic mutations thus far described in breast carcinoma. Unlike ovarian carcinoma, PIK3CA is not subject to amplification in breast tumorigenesis, but the observation of AKT2 amplification and PIK3CA mutation in breast cancers again implicates the PI3K-AKT pathway as among the most important yet described in sporadic breast tumorigenesis.
References

Frequent Mutation of the *PIK3CA* Gene in Ovarian and Breast Cancers


*Clin Cancer Res* 2005;11:2875-2878.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/8/2875

Cited articles
This article cites 12 articles, 5 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/8/2875.full#ref-list-1

Citing articles
This article has been cited by 50 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/11/8/2875.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/11/8/2875.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.